A number of investment brokers have recently updated their price targets on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/01/2016 – Arena Pharmaceuticals, Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 1.5 price target on the stock.

01/26/2016 – Arena Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Needham & Company.

10/28/2015 – Arena Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at WallachBeth Capital. They now have a USD 4 price target on the stock.

07/15/2015 – Arena Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 4.5 price target on the stock.

05/13/2015 – Arena Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 9 price target on the stock.

03/06/2015 – Arena Pharmaceuticals, Inc. was downgraded to “underperform” by analysts at Zacks. They now have a USD 4 price target on the stock.

10/20/2014 – Arena Pharmaceuticals, Inc. had its “underperform” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 5 price target on the stock.

09/04/2014 – Credit Suisse began new coverage on Arena Pharmaceuticals, Inc. giving the company a “underperform” rating. They now have a USD 3.5 price target on the stock.

04/25/2014 – Wells Fargo began new coverage on Arena Pharmaceuticals, Inc. giving the company a “market perform” rating.

11/11/2013 – Arena Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 12 price target on the stock.

11/11/2013 – Arena Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 12 price target on the stock.

10/03/2013 – Cowen began new coverage on Arena Pharmaceuticals, Inc. giving the company a “market perform” rating. They now have a USD 4.5 price target on the stock.

The share price of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was down -0.95% during the last day of trading, with a day high of 1.61. 1919978 shares were traded during the last session.

The stock’s 50 day moving average is 1.83 and its 200 day moving average is 1.79. The stock’s market capitalization is 378.88M. Arena Pharmaceuticals, Inc. has a 52-week low of 1.30 and a 52-week high of 5.12.

View other investors thoughts on Arena Pharmaceuticals, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.